Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer.
Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer.
复制标题
DOI：
10.5402/2012/245756
复制
发表时间：
2012-01-01
期刊：
影响因子：
--
通讯作者：
Ravaggi, Antonella
中科院分区：
文献类型：
--
作者：
Bandiera, Elisabetta;Franceschini, Roberta;Ravaggi, Antonella
导论.我们进行了文献回顾，以阐明血清血管内皮生长因子（sVEGF）水平在卵巢癌中的潜在预后意义。方法.从VEGF发现到2011年10月，在MEDLINE/PubMed中确定了英语和意大利语的合格研究。所有研究评价：（i）任何手术和化疗治疗前的sVEGF水平;（ii）sVEGF水平与既定预后变量之间的关系;（iii）sVEGF水平在预测患者预后中的价值。结果搜索结果为758个标题。9项研究符合纳入标准。至少有一项研究发现sVEGF水平与FIGO分期、肿瘤分级、残留肿瘤大小、淋巴结受累和腹水存在之间存在统计学显著相关性。sVEGF与已建立的预后因素相比，似乎是总生存期的最佳预后标志物，因为它在大多数研究中作为独立的预后因素而突出。此外，在3项将DFS视为终点的研究中，有2项研究显示sVEGF水平是独立的预后因素。结论高水平的sVEGF确定了具有较高死亡和/或复发风险的患者亚组。这些患者应该有资格接受个性化的治疗干预。
Introduction. We performed a review of the literature to elucidate the potential prognostic significance of serum vascular endothelial growth factor (sVEGF) levels in ovarian cancer. Methods. Eligible studies in English and Italian were identified in MEDLINE/PubMed from VEGF discovery to October 2011. All studies evaluating: (i) sVEGF levels before any surgical and chemotherapeutic treatment; (ii) the association between sVEGF levels and the established prognostic variables; (iii) the value of sVEGF levels in predicting patients' outcomes, were selected for this review. Results. The search resulted in 758 titles. Nine studies met the inclusion criteria. A statistically significant association between the level of sVEGF and FIGO stage, tumour grade, residual tumour size, lymph node involvement, and presence of ascites was found in at least one study. sVEGF, in comparison with the established prognostic factors, appears to be the best prognostic marker for overall survival, since it stands out as an independent prognostic factor in most of the studies considered. Moreover, sVEGF levels were shown to be independent prognostic factors by 2 out of the 3 studies that considered DFS as an end point. Conclusion. High levels of sVEGF identify a subgroup of patients with higher risk of death and/or recurrence. These patients should be eligible for individually tailored therapeutic interventions.